EP2646008A1

EP2646008A1 - Transdermal therapeutic system (tts) comprising rotigotine

Info

Publication number: EP2646008A1
Application number: EP11790776.6A
Authority: EP
Inventors: Christian Drescher; Christian Janssen; Ulrich Becker; Armin Breitenbach
Original assignee: Ratiopharm GmbH
Current assignee: Ratiopharm GmbH
Priority date: 2010-11-29
Filing date: 2011-11-29
Publication date: 2013-10-09
Also published as: WO2012072650A1; EP2457565A1; EA201300648A1; US20130281944A1

Abstract

The present invention relates to a patch which comprises the active ingredient rotigotine and is intended for transdermal delivery of the active pharmaceutical ingredient rotigotine, comprising a backing layer (1), a matrix layer (2) which comprises the active ingredient, and a removable protective sheet (4) which is intended for removal before the patch is applied to the skin, characterized in that disposed with areal coverage between the matrix layer (2) and the removable protective sheet (4) is an additional interlayer (3).

Description

Title of the invention

"Transdermal Therapeutic System (TTS) containing rotigotine"

Field of the invention

The present invention relates to a rotigotine-containing patch for the transdermal delivery of the pharmaceutical active substance rotigotine, comprising a carrier layer (1), a matrix layer containing the active substance (2), a removable before application to the skin, peelable protective film ( 4), characterized in that between the matrix layer (2) and the peelable protective film (4) an additional intermediate layer (3) is applied over the entire area. description

Rotigotine [(-) - 5,6,7,8-Tetrahydro-6- [propyl [2- (2-thienyl) ethyl] amino] -1-naphthol] is a pharmaceutically active substance useful in the treatment of among others Crohn's

Parkinson is used. The only currently on the market rotigotine

Drug is a transdermal therapeutic system (TTS). Neupro from UCB contains the active substance embedded in a polymer matrix, in an amount above the saturation concentration. Supersaturated active substance / polymer systems are known to be metastable, ie under unfavorable conditions, the active substance may crystallize: For example, a recall campaign for NEUPRO had to be started because active ingredients crystallized out of the plasmas (see FIG Crystallized drug can cause a variety of problems: For example, less active ingredient is

Absorption through the skin available, whereby the intended administration rate can no longer be guaranteed. Crystallized active ingredient may also adversely affect the adhesive properties (adhesion or cohesion) of the adhesive matrix. Even today a cold chain is required for transport and storage of NEUPRO® and it is recommended to keep NEUPRO in the refrigerator.

In the prior art, for example WO 99/49852 or WO 2004/058247 so-called matrix systems are proposed for the production of rotigotine plasters, in which the active ingredient in a matrix of pressure-sensitive polymer adhesive ("Pressure sensitive adhesive")

It must always be compromised iss issuing polymer pressure-sensitive adhesive, since the adhesive sufficient solubility for the drug and

must have satisfactory adhesive properties at the same time. The development of a suitable TTS is further complicated by the fact that active ingredients in higher concentrations (Neupro®, for example, containing rotigotine base in a proportion of about 9% by weight) can considerably influence the adhesive properties of polymer matrices Adhesion, cohesion and the occurrence of the phenomenon of "cold flow".

In addition, self-adhesive polymers often contain free functional groups, such as hydroxyl (OH) or carboxyl (COOH) groups, which interact with the active ingredient and can thereby adversely affect its crystallization and release behavior.

Starting from the prior art, the object is to provide a rotigotine TTS, which allows the independent optimization of the adhesive properties and the release behavior.

This object has been achieved by providing a drug containing the active ingredient rotigotine transdermal therapeutic system (TTS) with a drug-impermeable carrier layer (1), containing the active ingredient

Matrix layer (2), and a peelable protective film (4) to be removed before application to the skin, characterized in that between the

Matrix layer (2) and the peelable protective film (4) an intermediate layer (3) is applied across the surface.

While the matrix layer (2) determines the release properties for the active ingredient, the adhesive properties of the TTS are determined by suitable choice of the intermediate layer (3). Due to the inventive structure of the TTS so the release properties for the drug and the

Adhesive properties of the patch are modulated independently.

Since in such a system for the matrix layer (2) and non-self-adhesive polymers can be used, are also the

Choices of the usable for the stock polymers significantly increased. Non-self-adhesive polymers in the context of this invention are those whose

Adhesive strength is insufficient, so that a TTS invention over the entire Administration period on the human skin -without further aids-adheres. Examples of non-self-adhesive polymers are polymers with longer aliphatic chains and / or those without functional groups.

Functional groups such as carboxyl groups, which are usually responsible for the adhesive properties of a polymer, may interact in an undesirable manner with basic drugs such as rotigotine, e.g. through salt formation. In contrast, polymers without these functional groups may have preferred dissolution and release properties for the active ingredient.

A preferred embodiment of the invention therefore relates to a TTS with an active substance-impermeable support layer (1), a matrix layer containing the active substance (2), to be removed before application to the skin,

peelable protective film (4) and between the matrix layer (2) and the peelable protective film (4) surface-mounted intermediate layer (3), characterized in that the matrix layer (2) consists of a non-self-adhesive polymer.

Another advantage of the invention is that for the intermediate layer (3), such polymers are used, due to a very low

Solubility for rotigotine as a material for the stock (2) are not readily considered.

[001 1] FIG. 2 shows the schematic structure of a TTS of a self-adhesive matrix layer containing

An active substance-impermeable support layer (1)

A self-adhesive matrix layer containing rotigotine (2)

- One between the matrix layer (2) and the peelable protective film (4)

comprehensive interlayer (3)

At least one peelable protective film (4) to be removed before application to the skin

Fig. 3 shows the schematic structure of a TTS with non-adhesive matrix layer containing An active substance-impermeable support layer (1)

A rotigotine-containing matrix layer, non-adhesive (2)

A first, between the matrix layer (2) and the peelable protective film

(4) full-surface intermediate layer (3)

- At least one to be removed before application to the skin,

peelable protective film (4)

A second intermediate layer (5), which is applied in a covering manner between the matrix layer (2) and the carrier layer (1)

The area-wide shielding of the matrix layer (2) by the

Intermediate layer (3) also has the additional advantage of avoiding direct contact of the reservoir with the cut edges of the peelable protective film (4) to be removed before applying to the skin, which obviously led to crystal formation in the marketed product Neupro® (see FIG. 1 ).

The active substance-impermeable support layer (1) of the plaster according to the invention is impermeable to the active ingredient and the compounds contained in the active substance-containing layer and inert, i. E. there is also no migration into the carrier layer. The active substance-impermeable carrier layer can be permeable to air and water, but is preferably occlusive. On the one hand, it has to have a certain rigidity so that it sufficiently stabilizes the active substance-containing matrix layer (2) so that the TTS can be handled, but on the other hand it must also have a certain sufficient flexibility so that even larger TTS patches can still adapt to the skin to ensure sufficient comfort.

The active substance impermeable carrier layer (1) consists of polymers such as polyesters (for example PET), polyolefins (for example PE), polycarbonates, polyethylene oxides, polyurethanes, polystyrenes, polyamides, polyvinyl acetates and polyvinyl chlorides. Preference is given to an aluminum-vapor-deposited PE / PET carrier layer (for example Scotchpak 1 109, 3M).

As materials for the rotigotine-containing matrix layer (2), film-forming polymers such as e.g. Polyacrylates, ethylene / ethyl acrylate

Copolymers, Poliisobutylene (PIB), as well as polysiloxanes. Preference is given to acrylate Copolymers, for example those of the Eudragit® type.

In one embodiment, the rotigotine is preferably used in the form of the free rotigotine base.

The active ingredient-containing matrix layer (2) may contain excipients such as antioxidants, plasticizers, permeation promoters, solubilizers, crosslinkers, emulsifiers, preservatives and / or thickeners in addition to the pharmaceutical active ingredient rotigotine.

The active ingredient may be dissolved in the matrix layer (2) and / or dispersed. Preferably, the active ingredient is completely in dissolved form.

The solubility of the matrix layer (2) for the active ingredient rotigotine is between 4 and 30 wt .-%, preferably between 6 and 20 wt .-%, even more preferably between 8 and 15 wt .-%.

The active ingredient content of rotigotine in the matrix layer (2) is 4 to 30 wt .-%, preferably 6 to 20 wt .-%, more preferably 8 to 15 wt .-%, based on the total weight of the matrix layer ,

For the intermediate layer (3) are polymers based on

Silicones, polyacrylates, polyvinyl ethers, polyisobutylenes (PIB), styrene-isoprene or butadiene-styrene copolymers, polyolefins, polyvinyl acetates, polyamides and / or ethylene-vinyl acetate copolymers.

The intermediate layer (3) is preferably self-adhesive and preferably consists of a pressure-sensitive polymer adhesive ("pressure sensitive adhesive"), preferably of an amine-resistant silicone adhesive such as BIO-PSA Q7-4301 or BIO-PSA Q7-4201 (Dow Corning) ,

The intermediate layer (3) may optionally include adjuvants such as

Plasticizers, fillers, crosslinkers, preservatives and / or solvents and antioxidants.

The thickness of the intermediate layer (3) is between 4 and 25 pm, preferably between 8 and 20 pm and particularly preferably between 10 and 15 pm.

The intermediate layer can optionally also serve simultaneously as a control membrane for the active substance flow. The permeation of the active ingredient is reduced by not more than 20%, preferably not more than 10%. The intermediate layer should, in addition to its primary function, namely the

Regulation of the adhesive power, as little as possible interact with the drug. The solubility of the intermediate layer for the active ingredient is therefore preferably only 5% to 15% of the solubility of the matrix layer, preferably 5% to 10%. The ratio of the thickness of the matrix layer to the thickness of the intermediate layer is between 20: 1 and 3: 1, preferably between 10: 1 and 5: 1.

The peelable protective film (4) to be removed before application to the skin consists of polyethylene, polypropylene, polyesters (PET), polysiloxanes,

Polyvinyl chloride or polyurethane or optionally treated

Paper fibers and is preferably silicone, fluorosilicone or fluorocarbon polymer coated. Preferred is fluoropolymer-coated PET liner

(For example Scotchpak 1022, 3M).

In principle, the same materials as for the first intermediate layer (3) are suitable for the second intermediate layer (5). Preferably, both are made of the same material.

The TTS preferably has a structure as shown in Fig. 1 or Fig. 2. However, the TTS may additionally have an adhesive film ("overtape") with which the TTS is fixed on the skin.

The TTS has a size of 5 to 100 cm ² , preferably 10 to 50 cm ² . The basis weight of the TTS (without the peelable protective film) is 20 to 150 g / cm ² , preferably 30 to 100 g / cm ² , particularly preferably 40 to 70 g / cm ² .

In a preferred embodiment, the TTS has a bond strength of between 5 N / 25 mm ² and 100 N / 25 mm ² , preferably between 10 N / 25 mm ² and 50 N / 25 mm ² . The determination of the bond strength is carried out by means of known standard methods (eg ASTM D 1000-99).

The patch according to the invention is suitable for transdermal

Administration of rotigotine over 12 hours to 3 days, that is, the wearing period of a patch extends over this period. Preferred is a carrying period of 24h to 48h. Preferred release rates are in the range of 0.05 g / h to 1 g / h, preferably 0.1 to 0.5 pg / h, for a substantial portion of the administration period.

The TTS calls in a preferred embodiment, an average maximum Plasma concentration (c _max ) of rotigotine from 0.1 to 150 ng / mL, preferably 0.5 to 100 ng / mL, forth. In a further preferred embodiment, after repeated single applications, the TTS generates an AUC of 4.0 to 30 ng ^* h / ml_,

in particular 5.0 to 20 ng ^* h / ml_.

The preparation of the patch according to the invention is carried out according to known production methods. The production of rotigotine TTS in the context of this invention comprises, for example, the following steps:

a. Dissolve or suspend rotigotine base in a suitable

solvent

b. Add the solution / suspension to a polymer solution with stirring c. Coating a suitable carrier film (1) with the active substance-containing polymer solution

d. Drying with removal of the solvent, resulting in a first laminate of carrier film and rotigotine-containing matrix layer (2)

e. Coating a suitable protective film (4) with a suitable

polymer solution

f. Drying with removal of the solvent, wherein a second laminate of protective film (4) and drug-free intermediate layer (3) results

G. Joining the two laminates so that the matrix layer (2) and the separating layer (3) come to lie on one another (see figures) h. Punching patches of suitable size from the total laminate i. Pack the individual TTS in suitable containers

For TTS with a non-self-adhesive matrix layer, the carrier film (1) is first coated with a suitable polymer solution before the application of the matrix layer (process step c) and then dried.

One aspect of the present invention relates to a transdermal

therapeutic system (TTS) comprising the active ingredient rotigotine in the form of the free base, comprising a drug-impermeable carrier layer (1), a matrix layer containing the active substance (2), a peelable, polymer-coated protective film (4) to be removed before application to the skin a surface-mounted between the matrix layer (2) and the peelable protective film (4)

Intermediate layer (3), characterized in that the matrix layer (2) consists of a pressure-sensitive polymer adhesive in which the active ingredient is completely dissolved. An embodiment of this aspect of the invention relates to a transdermal therapeutic system (TTS) containing the active ingredient rotigotine in the form of the free base, comprising a drug-impermeable carrier layer (1), a matrix layer containing the active substance (2), one before application to the Skin removable, peelable, polymer coated protective film (4) and a between the matrix layer (2) and the peelable protective film (4) surface-mounted intermediate layer (3), characterized in that the matrix layer (2) consists of a pressure-sensitive polyacrylate adhesive and between 8 and 15 wt .-% completely dissolved active ingredient.

In certain embodiments of this aspect of the invention that is

Basis weight of the TTS between 30 g / cm and 100 g / cm and the ratio of the thickness of the matrix layer (2) to the thickness of the intermediate layer (3) is between 10: 1 and 5: 1.

In another embodiment of this aspect of the invention, the transdermal therapeutic system (TTS) is characterized in that between the matrix layer (2) and the carrier layer (1), a second intermediate layer (5) is applied across the surface.

Alternatively to the use of rotigotine as the free base, rotigotine can also be used as ionic liquid for the preparation of the TTS according to the invention. The term "ionic liquid" as used herein refers to salts (i.e.

Compositions comprising organic cations and organic anions) having a melting point below 40 ° C, preferably below 32 ° C. Such an ionic liquid comprises at least one rotigotine cation and at least one type of counterion obtainable from an organic compound, or at least one rotigotine anion and at least one kind of counterion obtainable from an organic compound.

It has been found that rotigotine as a cation or as an anion with organic compounds can form ionic liquids which can be readily prepared with a variety of pharmaceutically acceptable organic compounds. These ionic rotigotine fluids exhibit high thermal stability and, in particular, do not cause any problems due to crystallization, such as exist for the free base and the other salts known in the art. Furthermore, they have the advantage that there are no problems associated with the existence of polymorphic forms of the crystalline compound. Agents that exist in several polymorphic forms are often unstable when stored in the form of pharmaceutical preparations. Since changes in the crystal form can have far-reaching effects on the physicochemical parameters of a substance, it is advantageous to be able to circumvent the solid state.

The ionic liquids are composed of at least one rotigotine cation and at least one kind of anion, or alternatively of at least one rotigotine anion and at least one kind of cation. It will be understood by those skilled in the art that the disclosed ionic liquids may contain a rotigotine cation with more than one type of anion (eg, 2, 3, or more different types of anions). However, an anion is preferred. It will also be understood by those skilled in the art that the disclosed ionic liquids may contain a rotigotine anion having more than one type of cation (e.g., 2, 3, or more different types of cations). However, a cation is preferred. The ions are preferably pharmaceutically acceptable. The use of all anions or cations defined below or the rotigotine salts formed with these counterions in the above-defined TTS are the subject matter of the present invention, provided that the melting point of these rotigotine salts is below 40 ° C., preferably below 32 ° C. (ie, liquid rotigotine salts).

In a preferred embodiment, the stoichiometry of the rotigotine ion to the counterion in the ionic liquid is between 1: 3 and 1: 1, preferably 1: 2 or 1: 1, and most preferably close to 1: 1.

In another embodiment, the ionic liquid comprises a rotigotine cation and at least 50% anions of an organic acid.

Accordingly, compositions comprising rotigotine salts having various anions of organic and inorganic acids, such as HCl, of the invention are also included when at least 50% of the anions are from one

derived organic acid.

In a further embodiment, the organic compound from which the counterion is derived has a lipophilic character which is characterized by a value of

Distribution coefficient log P of more than 0 is defined. It is preferred that said lipophilic compound has a log P of> 1, more preferably of more than 2, more preferably more than 3, and most preferably more than 4.

In certain embodiments, the counterion as the organic compound has the following properties:

1 . a distribution coefficient log P in a range between 0 and 6;

2. a molecular weight of 100 to 500;

3. Number of atoms from 20 to 70.

In a further embodiment, the invention relates to the

Use of compositions comprising a rotigotine salt in the transdermal therapeutic systems (TTS) according to the invention, wherein at least 1%, preferably at least 2%, 5%, 10%, 20%, 30%, 40% or even 50% of the Salt is an ionic liquid. Accordingly, in addition to the ionic liquid of rotigotine, such a composition may also include rotigotine salts, such as solid salts, having various anions other than ionic liquids. In such compositions, the ionic liquid content of rotigotine is therefore at least 1%, preferably at least 2%, 5%, 10%, 20%, 30%, 40% or even 50% of the total content of rotigotine salt in this composition. Cations as counterions

In certain embodiments of the invention, the ionic

A liquid of rotigotine a rotigotine anion and a cationic counterion selected from the group of cations defined below.

Quaternary Ammonium Compounds Specific examples of cations which may be present in the ionic liquid are compounds containing a nitrogen atom. Nitrogen atoms can exist as positively charged quaternary ammonium species or be transformed into such, for example by alkylation or protonation of the nitrogen atom. Accordingly, compounds that are a quaternary

Contain nitrogen atom (known as quaternary ammonium compounds (QACs)) typically cations. Any compound containing a quaternary nitrogen atom or a nitrogen atom that can be transformed into a quaternary nitrogen atom may be a cation of the invention for the disclosed ionic liquids.

According to the invention, the ionic liquid comprises a rotigotine anion and at least one quaternary amine of the formula (I)

R ¹ R ² R ³ RN ⁺ (I)

wherein R ¹ , R ² , R ³ , and R ^{4 may} each independently be H, optionally substituted C 1 -C 5 alkyl or alkenyl, optionally substituted C 6 -C 10 cycloalkyl, optionally substituted C 6 -C 12 aryl, optionally substituted C 7 -C 12 aralkyl, or wherein R ¹ and R ^{2 taken} together represent an optionally substituted C 4 -C 10 alkylene group and thereby form a 5-membered heterocyclic ring with the nitrogen atom of the formula (I), and wherein the term "optionally substituted" means that the group in question with a or more radicals, preferably between 0 and 6 radicals, selected from OH, SH, SR ⁵ , Cl, Br, F, I, NH ₂ , CN, NO ₂ , COOR ⁵ CHO, COR ⁵ and OR ⁵ , wherein R ^{5 is} a C1-C10 alkyl or

Cycloalkyl group is substituted or unsubstituted. In a preferred embodiment, R ^{1 is} a C ¹ -C 5 alkyl or alkenyl radical. Tetraalkyl ammonium

In other embodiments of the invention, the cationic counterion is a tetraalkylammonium cation. By way of example, a tetraalkylammonium cation may be a long chain alkyl group (eg, having a length of 10 or more

Carbon atoms) and three short chain alkyl groups (eg, having a length of less than 10 carbon atoms).

The ionic liquids may also contain an aliphatic benzylalkyl ammonium cation. An aliphatic benzylalkylammonium cation is a cation comprising an aliphatic group bonded to the nitrogen atom of a benzylalkylamine. The aliphatic group may be as described herein. The benzylalkylamine group may be a benzylamine, wherein the amine is attached to an alkyl or cycloalkyl group as described herein. One or more types of aliphatic benzylalkylammonium cations may be used in the ionic liquids are used.

In certain embodiments of this aspect of the invention, the aliphatic benzylalkylammonium cation is represented by the formula given below:

wherein R ^{10 represents} an aliphatic group as described above, and R ¹¹ and R ¹² independently represent alkyl or cycloalkyl groups as described herein. In some embodiments, one or more of the "R" substituents may be a long chain alkyl group (ie, having 10 or more

Carbon atoms). In other embodiments, one or more of the "R" substituents may be a short chain alkyl group (ie, having fewer than 10 carbon atoms). In other embodiments, one of the "R" substituents may be one long chain alkyl group and the other two "R" substituents be short chain alkyl groups.

In a further embodiment, the aliphatic

Benzylalkylammonium cation have each of the alkyl groups described herein bonded to each benzylalkylamine group described herein. In special

For example, R ¹⁰ in the formula of the aliphatic benzylalkylammonium cation may be an aliphatic group of from 10 to 40 carbon atoms, e.g. A decyl-docecyl (lauryl), tetradecyl (myristyl), hexadecyl (palmityl or cetyl),

Octadecyl (stearyl), or eicosyl (arachidyl) group, and R ¹¹ and R ¹² may each independently be a methyl, ethyl, propyl, butyl, pentyl, or hexyl group.

In other embodiments, the aliphatic benzylalkylammonium cation may include, but is not limited to, alkyldimethylbenzylammonium cations. Specific, non-limiting examples of alkyldimethylbenzylammonium cations include cetyldimethylbenzylammonium,

Lauryldimethylbenzylammonium, myristyldimethylbenzylammonium,

Stearyldimethylbenzylammonium and arachidyldimethylbenzylammonium. In other embodiments, the aliphatic benzylalkylammonium cation may include, but is not limited to, alkylethylmethylbenzylammonium cations. Specific, non-limiting examples of alkylethylmethylbenzylammonium cations include cetylethylmethylbenzylammonium,

Laurylethyl-methylbenzylammonium, myristylethylmethylbenzylammonium,

Stearylethylmethyl-benzylammonium and arachidylethylmethylbenzylammonium.

Dialiphatic dialkyl ammonium

Further examples of QACs which can be used for the ionic liquids are the dialiphatic dialkylammonium cations. One

dialiphatic dialkylammonium cation is a compound comprising two aliphatic groups and two alkyl groups bonded to the nitrogen atom. The aliphatic groups may be identical or different and may include any aliphatic group as described above. The alkyl groups may be identical or different and may include any alkyl group as described above. In the dialkyl dialkyl ammonium cations disclosed, the two aliphatic groups may contain ten or more carbon atoms and the two alkyl groups may contain less than ten carbon atoms. Alternatively, the two aliphatic groups may contain less than ten carbon atoms and the two alkyl groups may contain ten or more carbon atoms. One or more types of dialkyl dialkylammonium cations can be used in the ionic liquids.

In particular embodiments, the dialiphatic dialkylammonium cation may be didodecyldimethylammonium, ditetradecyldimethylammonium, dihexadecyldimethylammonium, and the like, including combinations thereof.

Other cations

In a specific embodiment of the invention, choline esters (e.g., acetylcholine) may be used as the counterion. Choline esters can pass through

Esterification of a compound with a carboxyl group or by transesterification of a compound with an ester group with a choline unit. Further examples of choline esters are bethanechol, carbachol, citocolin,

Methacholine, succinylmonocholine, suxamethonium chloride. In a special Embodiment, choline can be used as a counterion.

Further examples of preferred cations are (2-hydroxyethyl) - dimethylundecyl-oxymethyl-ammonium, (2-acetoxyethyl) -heptyloxymethyldimethyl-ammonium, (2-acetoxyethyl) -dodecyloxymethyldimethyl-ammonium and mepenzolate.

In another embodiment, the cationic counterions are derived from an arylamine, which is preferably ethyleneamine or piperazine.

In a further embodiment, the cationic counterions are derived from an alkylamine containing hydroxy groups, which is preferably diethanolamine, triethanolamine, tromethamine or N-methylglucamine.

In a preferred embodiment, ionic liquids based on amine bases of high lipophilicity, such as benzathine, 4-phenylcyclohexylamine, benethamine and hydrabamine, are used.

In a further preferred embodiment, the ionic

Liquid a rotigotine anion and a Ν, Ν, Ν-trimethylethanolammonium cation (choline).

Anions as counterions

In other embodiments of this aspect of the invention, an organic acid is used for the preparation of the ionic liquid. This organic acid preferably has the formula R-COOH, where R is a saturated or monounsaturated, branched or unbranched C 3 -C 16 -hydrocarbon radical. This hydrocarbon radical has 3 to 16, more preferably 5 to 16

Carbon atoms. In a further embodiment, R preferably represents a saturated, monounsaturated or polyunsaturated, unbranched C 3 -C 16 -hydrocarbon radical, more preferably a C 5 -C 6 -hydrocarbon radical.

Examples of preferred acids of the formula R-COOH are propionic, butyric, pentanoic, hexanoic, heptanoic, octanoic, nonanoic, decanoic, undecanoic, lauric, tridecanoic, myristic,

Pentadecanoic acid, and palmitic acid. Octanoic acid is particularly preferred.

In another embodiment, the organic acid has the formula R'- COOH, where R 'represents a polyunsaturated, branched or unbranched C 1-8-C22 hydrocarbon radical.

Examples of preferred acids of the formula R'-COOH are linoleic acid, alpha-linoleic acid, arachidonic acid, eicosapentic acid and docosahexenoic acid. Linoleic acid is particularly preferred. Other suitable anions may be long chain

Alkyl sulfonic acids (for example, lauryl sulfonic acid), saccharin or acesulfame can be obtained.

In certain embodiments of this aspect of the invention, the anionic counterion is derived from a lipophilic monovalent acid. Preferably, the anionic counterion of a lipophilic monovalent acid represents at least 50% of the anions within the ionic liquid. The lipophilic monovalent acid is preferably octanoic acid.

Process for the preparation of ionic liquids

There are basically three methods for producing an ionic one

Liquid:

(1) Metathesis of a salt of the desired cation (for example, a halide salt) with a salt of the desired anion (for example, a transition metal (such as silver) salt, salts of Groups I or II, or an ammonium salt.) Such reactions can be carried out with many types of

Salts are carried out.

(2) An acid-base neutralization reaction.

(3) Replacement of the relevant ion by addition of a stronger acid or base. The combination of rotigotine with a counter cation in one

Solvent with optional heating may therefore serve to produce ionic liquids.

Preparation of an ionic liquid of rotigotine using an organic acid:

The ionic liquid of rotigotine and an organic acid as the The anion-forming reagent can be prepared by mixing rotigotine and acid and recovering the ionic liquid. In one embodiment, the mixing step is carried out in the absence of any solvent. This has the advantage that it is not necessary to remove the solvent after the formation of the ionic liquid, and also the process

environmentally friendly. Another advantage of the absence of solvent is that the resulting ionic liquid contains no solvent residues.

Alternatively, rotigotine and organic acid may also be mixed in the presence of one or more solvents. In this case, either the

Rotigotine or the rotigotine and the acid in the same or different

Solvents are suspended or dissolved before the mixing step takes place.

For example, first the rotigotine can be dissolved in a solvent, and the acid can then be added to this solution. Suitable solvents are, for example, water, alcohols, ethers, ketones, chlorinated

Solvents, and mixtures thereof. Preferred solvents are the ethers and the ketones.

Preparation of an ionic liquid of rotigotine using an amine:

The ionic liquid of rotigotine and an amine as the cation-forming reagent can be prepared by mixing rotigotine or a suitable acid addition salt of rotigotine and the corresponding amine and optionally an additional base in the presence of one or more solvents. In this case, the rotigotine, the amine and / or the additional base may be suspended or dissolved in the same or different solvents before the mixing step. For example, rotigotine may be dissolved in the solvent and the amine and optional additional base subsequently added to this solution. Suitable solvents include, for example, water, alcohols, ethers, ketones, chlorinated solvents, and mixtures thereof. Preferred solvents are alcohols. The optional

additional base is a strong base, such as hydroxides or hydrides. Preferred optional additional bases are sodium hydroxide and potassium hydroxide. Example 1: Ionic liquid containing a rotigotine cation and an octanoate anion

Example 1 a: 1 equivalent of octanoic acid is added to a solution of rotigotine (1 equivalent) in diisopropyl ether (5 times the volume) under nitrogen. After stirring (1 h), the solvent is removed in vacuo at 30 ° C. Drying under high vacuum for 2 h gives an oil in quantitative yield.

Example 1 b: Rotigotine (1 equivalent) is added in a glass ampoule to one equivalent of octanoic acid. The mixture is shaken for 1 h, forming a homogeneous oil.

Example 2: Ionic liquid containing a rotigotine anion and a choline cation

Example 2a: Rotigotine (1 equivalent) is dissolved in a round bottom flask in methanol (5 volumes). Potassium hydroxide (1 equivalent) and choline chloride (1 equivalent) are added and the mixture is stirred at room temperature for 1 h.

Acetone (5 volumes) is added and the solution filtered through a fine filter. The filtrate is concentrated in vacuo at room temperature and dried under high vacuum. As the product, an oily residue is obtained in quantitative yield.

Example 2b: Rotigotinhydrochlond (1 equivalent) is dissolved in a round bottom flask in methanol (5 volumes). Potassium hydroxide (2 equivalents) and choline chloride (1 equivalent) are added and the mixture is stirred at room temperature for 1 h. Acetone (5 volumes) is added and the solution filtered through a fine filter. The filtrate is concentrated in vacuo at room temperature and dried under high vacuum. As the product, an oily residue is obtained in quantitative yield.

Claims

claims

1 . Transdermal Therapeutic System (TTS) containing the active ingredient rotigotine or one of its pharmaceutically acceptable salts with a

active substance-impermeable carrier layer (1), one containing the active substance

Matrix layer (2) and a peelable protective film (4) to be removed before application to the skin, characterized in that between the

Matrix layer (2) and the peelable protective film (4) a first intermediate layer (3) is applied across the surface.

2. TTS according to claim 1, wherein the first intermediate layer (3) consists of a pressure-sensitive polymer adhesive.

3. TTS according to claim 1, wherein the matrix layer (2) consists of non-adhesive polymers having longer aliphatic chains, preferably polyacrylate esters having 4 to 8 carbon atoms and a second intermediate layer (5), which consists of the same material as the first intermediate layer (3) exists.

4. TTS according to one of the preceding claims, wherein the thickness of the intermediate layer or intermediate layers is in each case between 4 m and 25 m, preferably between 8 m and 20 m and particularly preferably between 10 m and 15 pm.

5. TTS according to any one of the preceding claims, wherein the active ingredient is the free rotigotine base.

6. TTS according to any one of claims 1 -4, wherein the active ingredient is rotigotine in the form of an ionic liquid, wherein the ionic liquid (a) at least one rotigotine cation and at least one kind of counterions, obtainable from an organic compound , or

(b) at least one rotigotine anion and at least one type of counterion obtainable from an organic compound.

7. TTS according to claim 6, wherein the ionic liquid comprises at least one rotigotine cation and at least one kind of counterions, wherein the

Gegenion is an anion of an organic acid.

8. TTS according to claim 7, wherein the organic acid is selected from: (i) a compound of the formula R-COOH, wherein R is a saturated or simple unsaturated, branched or unbranched C3-C16 hydrocarbon radical, or

(ii) a compound of the formula R'-COOH, wherein R 'represents a polyunsaturated, branched or unbranched C 18 -C 22 hydrocarbon radical.

9. TTS according to claim 7 or 8, wherein the organic acid is selected from propionic acid, butyric acid, pentanoic acid, hexanoic acid, heptanoic acid,

Octanoic, nonanoic, decanoic, undecanoic, lauric, tridecanoic, myristic, pentadecanoic, palmitic and unsaturated analogs thereof.

10. TTS according to any one of claims 7-9, wherein the organic acid

Octanoic acid is.

1 1. TTS according to claim 6, wherein the ionic liquid comprises at least one rotigotine anion and at least one kind of counterions, wherein the

Counterion is a cation derived from an amine.

12. TTS according to claim 1 1, wherein said amine anion is selected from:

(i) an amine of the formula (I)

R ¹ R ² R ³ RN ⁺ (I)

Cycloalkyl group, substituted or unsubstituted;

(ii) a tetraalkylammonium ion;

(iii) an aliphatic heteroarylammonium ion;

(iv) a dialiphatic dialkyl ammonium cation.

13. TTS according to claim 12, wherein said amine anion is selected from an amine of formula (I) wherein R ^{1 is} a C ¹ -C 5 alkyl or alkenyl.

14. TTS according to claim 1 1, wherein the amine is selected from diethanolamine, triethanolamine, ethyleneamine, trimethamine, N-methylglucamine, piperazine, benzathine, 4-phenylcyclohexylamine, benethamine and hydrabamine.

15. TTS according to claim 1 1, wherein the counterion is a Ν, Ν, Ν-trimethylethanol ammonium cation.

16. TTS according to any one of claims 1 -4, comprising a rotigotine salt, wherein at least 1% by weight, preferably at least 2% by weight, and more preferably at least 5, 10, 20, 30, 40, or 50% by weight of the salt an ionic one

Liquid as defined in any one of claims 6-15.

17. TTS according to any one of the preceding claims, wherein the active ingredient is completely dissolved in the matrix layer (2).

18. TTS according to any one of the preceding claims, wherein the solubility of the intermediate layer for the active ingredient is between 4 and 30 wt .-%, preferably between 6 and 20 wt .-%, even more preferably between 8 and 15 wt .-%.

19. TTS according to one of the preceding claims, wherein the

Active substance content of rotigotine, based on the free base, in the matrix layer (2) is between 4 to 30% by weight, preferably 6 to 20% by weight, more preferably 8 to 15% by weight.

20. TTS according to any one of the preceding claims, wherein the solubility of the intermediate layer or intermediate layers for the active ingredient is 5% to 15%, preferably 5% to 10%, of the solubility of the matrix layer for the active ingredient.

21. TTS according to one of the preceding claims, wherein the ratio of the thickness of the matrix layer (2) to the thickness of the first intermediate layer (3) is between 20: 1 and 3: 1, preferably between 10: 1 and 5: 1.

22. TTS according to one of the preceding claims, wherein the TTS has a size of 5 cm ² to 100 cm ² , preferably 10 cm ² to 50 cm ² .

23. TTS according to one of the preceding claims, wherein the TTS has an adhesive force of between 5 N / 25 mm ² and 100 N / 25 mm ² , preferably between 10 N / 25 mm ² and 50 N / 25 mm ² .

24. TTS according to any one of the preceding claims, wherein the TTS is suitable for administration of rotigotine for 12 h to 3 days, preferably for 24 h to 48 h.

25. TTS according to one of the preceding claims, wherein the

Release rate is a substantial part of the administration period in the range of 0.05 g / h to 1 g / h, preferably 0.1 g / h to 0.5 g / h.

26. TTS according to one of the preceding claims, wherein the TTS for a substantial part of the administration period, a mean maximum plasma concentration (Cmax) of rotigotine from 0.1 ng / mL to 150 ng / mL, preferably 0.5 ng / mL to 100 ng / mL generated.